The Role of Pulmonary Surfactant in COVID-19 Understanding

References (102)

1. 1 Coronaviruses: An Overview of Their Replication and Pathogenesis [DOI]
2. 2 Receptor and viral determinants of SARS‐coronavirus adaptation to human ACE2 [DOI]
3. 3 Immunoregulatory functions of surfactant proteins [DOI]
4. 4 ARTIFICIAL SURFACTANT THERAPY IN HYALINE-MEMBRANE DISEASE [DOI]
5. 5 The role of lipids in pulmonary surfactant [DOI]
6. 6 Surfactant Proteins A and D and Pulmonary Host Defense [DOI]
7. 7 In Vivo Lung Lavage as an Experimental Model of the Respiratory Distress Syndrome [DOI]
8. 8 Current perspectives in pulmonary surfactant — Inhibition, enhancement and evaluation [DOI]
9. 9 Structure of pulmonary surfactant membranes and films: The role of proteins and lipid–protein interactions [DOI]
10. 10 The Role of Surfactant in Lung Disease and Host Defense against Pulmonary Infections [DOI]
11. 11 Effect of Recombinant Surfactant Protein C–Based Surfactant on the Acute Respiratory Distress Syndrome [DOI]
12. 12 Serial Changes in Surfactant-associated Proteins in Lung and Serum before and after Onset of ARDS [DOI]
13. 13 TMPRSS2 Activates the Human Coronavirus 229E for Cathepsin-Independent Host Cell Entry and Is Expressed in Viral Target Cells in the Respiratory Epithelium [DOI]
14. 14 The discovery of angiotensin‐converting enzyme 2 and its role in acute lung injury in mice [DOI]
15. 15 Oxidant-Antioxidant Balance in Acute Lung Injury* [DOI]
16. 16 Structure-function relationships in pulmonary surfactant membranes: From biophysics to therapy [DOI]
17. 17 Surfactant phospholipid metabolism [DOI]
18. 18 What’s new in the renin-angiotensin system? [DOI]
19. 19 Phosphatidylcholine biosynthesis and function in bacteria [DOI]
20. 20 An Insight into the Diverse Roles of Surfactant Proteins, SP-A and SP-D in Innate and Adaptive Immunity [DOI]
21. 21 Collectins [DOI]
22. 22 A model of the ACE2 structure and function as a SARS-CoV receptor [DOI]
23. 23 Surfactant protein-D and pulmonary host defense [DOI]
24. 24 Biochemical and pharmacological differences between preparations of exogenous natural surfactant used to treat Respiratory Distress Syndrome: Role of the different components in an efficient pulmonary surfactant [DOI]
25. 25 Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25–29 weeks' gestation: a randomised trial [DOI]
26. 26 The SARS coronavirus spike glycoprotein is selectively recognized by lung surfactant protein D and activates macrophages [DOI]
27. 27 Understanding negative pressure pulmonary edema [DOI]
28. 28 Role of lipid ordered/disordered phase coexistence in pulmonary surfactant function [DOI]
29. 29 Pulsating bubble technique for evaluating pulmonary surfactant [DOI]
30. 30 Function and regulation of expression of pulmonary surfactant-associated proteins [DOI]
31. 31 Direct determination of surface tension in the lung. [DOI]
32. 32 Pulmonary surfactant and its apoproteins. [DOI]
33. 33 Surface tension at low lung volumes: Dependence on time and alveolar size [DOI]
34. 34 Surfactant phospholipids: synthesis and storage [DOI]
35. 35 Serum Levels of Surfactant Proteins A and D Are Useful Biomarkers for Interstitial Lung Disease in Patients with Progressive Systemic Sclerosis [DOI]
36. 36 Is surfactant therapy beneficial in the treatment of the term newborn infant with congenital diaphragmatic hernia? [DOI]
37. 37 The roles of surfactant proteins A and D in innate immunity [DOI]
38. 38 Surfactant Collectins and Innate Immunity [DOI]
39. 39 An Elevated Level of Cholesterol Impairs Self-Assembly of Pulmonary Surfactant into a Functional Film [DOI]
40. 40 Patients with ARDS show improvement but not normalisation of alveolar surface activity with surfactant treatment: putative role of neutral lipids [DOI]
41. 41 LAPLACE’S LAW AND THE ALVEOLUS: A MISCONCEPTION OF ANATOMY AND A MISAPPLICATION OF PHYSICS [DOI]
42. 42 Delivery and Performance of Surfactant Replacement Therapies to Treat Pulmonary Disorders [DOI]
43. 43 Immunocytochemical localization of the major surfactant apoproteins in type II cells, Clara cells, and alveolar macrophages of rat lung. [DOI]
44. 44 Bronchoscopic Surfactant Administration in Patients With Severe Adult Respiratory Distress Syndrome and Sepsis [DOI]
45. 45 Increased surface tension favors pulmonary edema formation in anesthetized dogs' lungs. [DOI]
46. 46 Synthetic Pulmonary Surfactant Preparations: New Developments and Future Trends [DOI]
47. 47 Exogenous surfactant therapy in 2013: what is next? who, when and how should we treat newborn infants in the future? [DOI]
48. 48 Serum Surfactant Protein D (SP-D) is a Prognostic Marker of Poor Outcome in Patients with A/H1N1 Virus Infection [DOI]
49. 49 Recent Advances into Understanding Some Aspects of the Structure and Function of Mammalian and Avian Lungs [DOI]
50. 50 The perfused rat lung as a model for studies on the formation of surfactant and the effect of Ambroxol on this process [DOI]
51. 51 SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor [DOI]
52. 52 Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding [DOI]
53. 53 COVID-19: consider cytokine storm syndromes and immunosuppression [DOI]
54. 54 Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation [DOI]
55. 55 Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV [DOI]
56. 56 Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection [DOI]
57. 57 Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia [DOI]
58. 58 [A pathological report of three COVID-19 cases by minimal invasive autopsies]. [DOI]
59. 59 TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection [DOI]
60. 60 Surface Tension of Lung Extracts [DOI]
61. 61 Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)? [DOI]
62. 62 Alveolar lipids in pulmonary disease. A review [DOI]
63. 63 Pulmonary embolism in patients with COVID-19: Time to change the paradigm of computed tomography [DOI]
64. 64 The Impact of COVID-19 on HIV Treatment and Research: A Call to Action [DOI]
65. 65 The Phospholipid Research Center: Current Research in Phospholipids and Their Use in Drug Delivery [DOI]
66. 66 Lipid–Protein and Protein–Protein Interactions in the Pulmonary Surfactant System and Their Role in Lung Homeostasis [DOI]
67. 67 Repurposing Antiviral Protease Inhibitors Using Extracellular Vesicles for Potential Therapy of COVID-19 [DOI]
68. 68 Thoughts on the alveolar phase of COVID-19 [DOI]
69. 69 Surfactant replacement therapy: from biological basis to current clinical practice [DOI]
70. 70 Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury [DOI]
71. 71 Structural and simulation analysis of hotspot residues interactions of SARS-CoV 2 with human ACE2 receptor [DOI]
72. 72 Lung Surfactant for Pulmonary Barrier Restoration in Patients With COVID-19 Pneumonia [DOI]
73. 73 Surfactant therapy for COVID-19 related ARDS: a retrospective case–control pilot study [DOI]
74. 74 Immunopathogenesis of SARS-CoV-2-induced pneumonia: lessons from influenza virus infection [DOI]
75. 75 How coronavirus survives for days on surfaces [DOI]
76. 76 Assessment of pulmonary surfactant in COVID-19 patients [DOI]
77. 77 Pneumonitis and Emphysema in sp-C Gene Targeted Mice [DOI]
78. 78 Acute lung injury: how to stabilize a broken lung [DOI]
79. 79 Reversal of Surfactant Protein B Deficiency in Patient Specific Human Induced Pluripotent Stem Cell Derived Lung Organoids by Gene Therapy [DOI]
80. 80 Exogenous pulmonary surfactant: A review focused on adjunctive therapy for severe acute respiratory syndrome coronavirus 2 including SP-A and SP-D as added clinical marker [DOI]
81. 81 Surfactant-based prophylaxis and therapy against COVID-19: A possibility [DOI]
82. 82 Covid‐19, ACE2 and the kidney [DOI]
83. 83 High dose folic acid is a potential treatment for pulmonary hypertension, including when associated with COVID-19 pneumonia [DOI]
84. 84 Co-aerosolized Pulmonary Surfactant and Ambroxol for COVID-19 ARDS Intervention: What Are We Waiting for? [DOI]
85. 85 Severity of Coronavirus Disease 2019 (COVID-19): Does Surfactant Matter? [DOI]
86. 86 Fetal lung liquid: secretion and reabsorption [DOI]
87. 87 SP-D and GM-CSF regulate surfactant homeostasis via distinct mechanisms [DOI]
88. 88 Dysfunction of pulmonary surfactant mediated by phospholipid oxidation is cholesterol-dependent [DOI]
89. 89 Roles of different hydrophobic constituents in the adsorption of pulmonary surfactant [DOI]
90. 90 Acute Respiratory Failure [DOI]
91. 91 Newer Strategies for Surfactant Delivery [DOI]
92. 92 More than Expectorant: New Scientific Data on Ambroxol in the Context of the Treatment of Bronchopulmonary Diseases [DOI]
93. 93 Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation [DOI]
94. 94 Journal of Biomolecular Structure and Dynamics [DOI]
95. 95 Advances in synthetic lung surfactant protein technology [DOI]
96. 96 Serum surfactant protein A and D may be novel biomarkers of COVID-19 pneumonia severity [DOI]
97. 97 SURFACTANTS VERSUS COVID-19 [DOI]
98. 98 Surfactant Dysfunction [DOI]
99. 99 The Structural and Physiologic Basis of Respiratory Disease [DOI]
100. 100 Pulmonary interstitial and capillary pressures estimated from intra-alveolar fluid pressures [DOI]
101. 101 International Journal of Molecular Sciences [DOI]
102. 102 International Journal of Environmental Research and Public Health [DOI]

Cited by 0

No indexed citations yet.

Related research

• COVID 19 Disease Caused by Coronavirus 2 (SARS-CoV-2) (Severe Acute Respiratory Syndrome) — shares topic coverage
• Assessment of Anxiety in Healthcare Providers Working in ICU during COVID-19 Pandemics — shares topic coverage
• Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19 — shares topic coverage
• Elevated Levels of Lactate Dehydrogenase Predicts Poor Outcomes for Patients with COVID-19: A Review — shares topic coverage
• Addressing the Challenges of Containing Covid-19 Spread in a Rural, Poor Area in India: A Case Study — shares topic coverage